Abstract
Genomic studies revealed two main components in the genetic architecture of schizophrenia, one constituted by common variants determining a distributed polygenic effect and one represented by a large number of heterogeneous rare and highly disruptive mutations. These gene modifications often affect neural transmission and different studies proved an involvement of metabotropic glutamate receptors in schizophrenia phenotype. Through the combination of literature information with genomic data from public repositories, we analyzed the current knowledge on the involvement of genetic variations of the human metabotropic glutamate receptors in schizophrenia and related endophenotypes. Despite the analysis did not reveal a definitive connection, different suggestive associations have been identified and in particular a relevant role has emerged for GRM3 in affecting specific schizophrenia endophenotypes. This supports the hypothesis that these receptors are directly involved in schizophrenia disorder.
Keywords: Metabotropic glutamate receptors, schizophrenia, antipsychotic drugs, gene variants, omics data, bioinformatics.
Graphical Abstract
Current Neuropharmacology
Title:The Role of Metabotropic Glutamate Receptor Genes in Schizophrenia
Volume: 14 Issue: 5
Author(s): Carlo Maj, Alessandra Minelli, Edoardo Giacopuzzi, Emilio Sacchetti and Massimo Gennarelli
Affiliation:
Keywords: Metabotropic glutamate receptors, schizophrenia, antipsychotic drugs, gene variants, omics data, bioinformatics.
Abstract: Genomic studies revealed two main components in the genetic architecture of schizophrenia, one constituted by common variants determining a distributed polygenic effect and one represented by a large number of heterogeneous rare and highly disruptive mutations. These gene modifications often affect neural transmission and different studies proved an involvement of metabotropic glutamate receptors in schizophrenia phenotype. Through the combination of literature information with genomic data from public repositories, we analyzed the current knowledge on the involvement of genetic variations of the human metabotropic glutamate receptors in schizophrenia and related endophenotypes. Despite the analysis did not reveal a definitive connection, different suggestive associations have been identified and in particular a relevant role has emerged for GRM3 in affecting specific schizophrenia endophenotypes. This supports the hypothesis that these receptors are directly involved in schizophrenia disorder.
Export Options
About this article
Cite this article as:
Maj Carlo, Minelli Alessandra, Giacopuzzi Edoardo, Sacchetti Emilio and Gennarelli Massimo, The Role of Metabotropic Glutamate Receptor Genes in Schizophrenia, Current Neuropharmacology 2016; 14 (5) . https://dx.doi.org/10.2174/1570159X13666150514232745
DOI https://dx.doi.org/10.2174/1570159X13666150514232745 |
Print ISSN 1570-159X |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-6190 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
- Forthcoming Thematic Issues
Related Articles
-
Vascular Contribution to Alzheimer Disease: Predictors of Rapid Progression
CNS & Neurological Disorders - Drug Targets Drug Therapy for Patients with Eating Disorders
Current Drug Targets - CNS & Neurological Disorders Inhibitors of the Endocannabinoid-Degrading Enzymes, or how to Increase Endocannabinoids Activity by Preventing their Hydrolysis
Recent Patents on CNS Drug Discovery (Discontinued) Best Practice for Atrial Fibrillation Patient Education
Current Pharmaceutical Design Pathway Crosstalk Analysis based on Signaling Pathway Impact Analysis in Alzheimer's Disease
Current Proteomics New Strategies for Immune-Mediated Anti-Viral Drug and Vaccine Development
Current Pharmaceutical Design Antioxidant Therapy for Prevention of Inflammation, Ischemic Reperfusion Injuries and Allograft Rejection
Cardiovascular & Hematological Agents in Medicinal Chemistry Current Therapeutic Options for Alzheimers Disease
Current Genomics Signaling Pathways Associated with Inflammatory Bowel Disease
Recent Patents on Inflammation & Allergy Drug Discovery Novel Therapeutic Approaches Based on the Targeting of Microenvironment-Derived Survival Pathways in Human Cancer: Experimental Models and Translational Issues
Current Pharmaceutical Design Reverse Ayurvedic Pharmacology of Ashwagandha as an Adaptogenic Anti-Diabetic Plant: A Pilot Study
Current Traditional Medicine Association Serum S100B Protein in Alzheimer’s Disease: A Case Control Study from South India
Current Alzheimer Research Why Antidiabetic Vanadium Complexes are Not in the Pipeline of “Big Pharma” Drug Research? A Critical Review
Current Medicinal Chemistry Advances in L-Type Calcium Channel Structures, Functions and Molecular Modeling
Current Medicinal Chemistry Imaging as a Strategy for Premortem Diagnosis and Staging of Tauopathies
Current Alzheimer Research Common Therapeutic Strategies for Diabetic Retinopathy and Glaucoma
Current Drug Therapy Effects of Dietary Non-Fiber Carbohydrates on Composition and Function of Gut Microbiome in Monogastrics: A Review
Protein & Peptide Letters Bridging Intravenous Thrombolysis Before Mechanical Thrombectomy for Large Artery Occlusion May be Detrimental with Thrombus Fragmentation
Current Neurovascular Research Herb-Drug Interactions: An Evidence Based Approach
Current Medicinal Chemistry Role of Retinoids, Rexinoids and Thyroid Hormone in the Expression of Cytochrome P450 Enzymes
Current Drug Metabolism